Disclaimer

GLP-3 Wiki is an independent informational resource. We are not affiliated with Eli Lilly, Novo Nordisk, Boehringer Ingelheim, Altimmune, or any pharmaceutical company.

Retatrutide is an investigational drug and has not been approved by the FDA, EMA, or any other regulatory agency for any indication. Tirzepatide, semaglutide, and other GLP-1 drugs covered on this site are approved for specific uses only — always check current labeling with a licensed clinician.

Nothing on this site is medical advice, a prescription, or a recommendation to use any drug, peptide, or supplement. Always consult a healthcare provider before making decisions about medication, dosing, or stopping/starting treatment.

Some articles discuss grey-market or research-peptide sources for transparency and harm-reduction reasons. We do not endorse and never recommend unregulated sources. Many carry legitimate risks — contamination, dosing errors, counterfeit ingredients — that are documented in the relevant articles.